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Introduction: The purpose of this study was to assess the safety and 
efficacy of gemcitabine and carboplatin with (arm A) or without (arm 
B) daily oral cediranib as first-line therapy for advanced non–small-cell 
lung cancer.
Methods: A lead-in phase to determine the tolerability of gem-
citabine 1000 mg/m2 on days 1 and 8, and carboplatin on day 1 at area 
under curve 5 administered every 21 days with cediranib 45 mg once 
daily was followed by a 2 (A):1 (B) randomized phase II study. The 
primary end point was confirmed overall response rate (ORR) with 
6-month progression-free survival (PFS6) rate in arm A as secondary 
end point. Polymorphisms in genes encoding cediranib targets and 
transport were correlated with treatment outcome.
Results: On the basis of the safety assessment, cediranib 30 mg daily 
was used in the phase II portion. A total of 58 and 29 evaluable patients 
were accrued to arms A and B. Patients in A experienced more grade 
3+ nonhematologic adverse events, 71% versus 45% (p = 0.01). The 
ORR was 19% (A) versus 20% (B) (p = 1.0). PFS6 in A was 48% (95% 
confidence interval: 35%–62%), thus meeting the protocol-specified 
threshold of at least 40%. The median overall survival was 12.0 versus 
9.9 months (p = 0.10). FGFR1 rs7012413, FGFR2 rs2912791, and 
VEGFR3 rs11748431 polymorphisms were significantly associated with 
decreased overall survival (hazard ratio 2.78–5.01, p = 0.0002–0.0095).
Conclusions: The trial did not meet its primary end point of ORR but 
met its secondary end point of PFS6. The combination with cediranib 
30 mg daily resulted in increased toxicity. Pharmacogenetic analysis 
revealed an association of FGFR and VEGFR variants with survival.
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(J Thorac Oncol. 2013;8: 79–88)
Platinum-based combination chemotherapy offers a modest survival advantage over best supportive care for good per-
formance status (PS) patients with advanced non–small-cell 
lung cancer (NSCLC).1–3 The Eastern Cooperative Oncology 
Group (ECOG) E4599 trial,4 showed that addition of the anti-
angiogenic agent bevacizumab to carboplatin and paclitaxel 
prolonged survival compared with chemotherapy alone and 
validated the decades-long hypothesis that the angiogenesis 
pathway plays a critical role in tumorigenesis and that its 
inhibition can result in clinical benefit.5 Because of toxicity, 
patients with squamous cell histology and history of hemop-
tysis were excluded from this pivotal trial.6,7
Cediranib is an oral tyrosine kinase inhibitor of 
all three VEGFRs (vascular endothelial growth factor 
receptors), PDGFR (platelet-derived growth factor receptor) 
and FGFR (fibroblast growth factor receptor) 1, 4, that has 
shown promising antitumor activity against a number of 
malignancies, including NSCLC in phase I studies. N0528 
was conceptualized shortly after the phase I study, combining 
cediranib with carboplatin/paclitaxel, reported in 2006 that 
full single-agent dose of cediranib of 45 mg once daily may 
be administered with standard doses of the combination.8,9 In 
2007, a few weeks before the activation of N0528, another 
phase Ib study of cediranib with cisplatin/gemcitabine 
in NSCLC reported that the protocol-defined maximum-
tolerated dose was not reached at the 45-mg level, although 
30 mg once daily dosing seemed to be better tolerated with 
protracted dosing.10,11 Variations in toxicities and response 
have been observed in all these studies.8–11 These phenotypic 
variations are often traceable to underlying genetic variations 
as a result of polymorphic genes encoding proteins that 
metabolize, transport, or are targets for the drug. Cediranib 
targets VEGFR, PDGFR, and FGFR family members and 
inhibits the function of the adenosine triphosphate (ATP)-
binding cassette (ABC) drug transporters such as ABCB1 
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and ABCC1, hence affecting drug efflux.12–14 Metabolism and 
transport mechanisms are often shared among drugs, therefore, 
genetic variation could affect the bioavailability of more than 
one drug when they are used in combination, as is the case for 
ABC drug transporters in this combination therapy. To date, 
there is no report indicating any association of polymorphisms 
in cediranib-related genes with treatment efficacy or toxicity, 
therefore, this exploratory pharmacogenetics correlative study 
focused on single-nucleotide polymorphisms (SNPs) of nine of 
the cediranib-related genes in the VEGFR and FGFR families, 
VEGFA, and the ABC transporter genes. We did not examine 
any cediranib metabolism genes in this initial exploratory 
study. We thus evaluated the efficacy, tolerability, and safety 
of cediranib with the often-used regimen of carboplatin and 
gemcitabine in patients with advanced NSCLC and examined 
angiogenesis markers, in addition to cediranib molecular 
target genes (VEGFR1–3 and FGFR1-3), VEGFA and ABC 
family transport genes (ABCB1 and ABCC1), and correlated 
these markers with clinical outcomes.
MATERIALS AND METHODS
Patients and Evaluations
Eligible patients had ECOG PS 0 to 1 and histologic 
or cytologic confirmation of measurable, chemotherapy-
naive, stage IIIB (with malignant pleural effusion) or stage 
IV NSCLC (American Joint Committee on Cancer staging 
6th edition criteria). Squamous histology was allowed. At the 
time of study concept, the evidence of harm in anti-VEGF 
therapies for this subset of patients was in the context of 
fatal hemoptysis. The controversy surrounding this limited 
data then was deemed inconclusive. Thus, this study allowed 
squamous histology as long as other exclusion criteria typi-
cally associated with this histology were not present (hemop-
tysis, cavitary lesions). Prior neoadjuvant or adjuvant therapy 
for lung cancer was allowed if more than 12 months had 
elapsed before registration. Patients needed to have adequate 
bone marrow, hepatic, and renal function. Patients who were 
pregnant and diagnosed with hemoptysis, cavitary lesions, 
untreated or symptomatic brain metastases, poorly controlled 
hypertension, or proteinuria more than 500 mg/24 hours were 
excluded. Tumor measurements, by Response Evaluation 
Criteria In Solid Tumors (RECIST), were obtained at least 
every 6 weeks. The protocol was approved by institutional 
review boards, and all patients were required to give written 
informed consent under federal and institutional guidelines. 
Common Terminology Criteria for Adverse Events version 3 
was used to grade the severity of toxicities encountered dur-
ing study period.
Study Treatment
All patients received gemcitabine 1000 mg/m2 on days 1 
and 8 and carboplatin dosed to an area under the serum con-
centration time curve of 5 on day 1 via intravenous infusion 
every 3 weeks for a maximum of six cycles. Patients in arm 
A also received once daily oral cediranib in combination with 
chemotherapy. Patients in arm A, with at least stable disease 
after the initial six cycles, could continue on maintenance 
cediranib until disease progression.
Accrual to the study was suspended for approximately 
11 weeks after the sixth patient was randomized to arm A for 
safety analysis. These patients were evaluated weekly during 
the first cycle of treatment for the occurrence of any dose-
limiting toxicity(DLT) defined as: Common Toxicity Criteria 
grade 3 or higher nonhematologic toxicities (nausea, vomit-
ing, or diarrhea were DLTs if severity was ≥grade 3 despite 
maximal use of antiemetic support or antidiarrheal agents, 
respectively), grade 4 thrombocytopenia, febrile neutropenia, 
or grade 4 neutropenia for more than 5 days, or any toxicity 
requiring cediranib dose interruption of more than 2 weeks.
Correlative Studies
DNA was extracted from blood samples at baseline 
for analysis of SNPs in the following cediranib target genes; 
FGFR1, FGFR2, FGFR3, VEGFA, FLT1 (VEGFR1), KDR 
(VEGFR2), FLT4 (VEGFR3), and the ABC transporter genes 
ABCB1 and ABCC1. These genes were chosen because they 
play a role in the transport of and serve as targets for cedi-
ranib. Acquisition of tagSNPs and genotyping were simi-
lar to that previously described.15 Plasma was processed at 
baseline and before cycle 3 for analysis using the Bio Plex 
Pro human angiogenesis magnetic bead-based multiplex 
assay (Bio-Rad Life Science Research, Hercules, CA). for 
angiopoietin- 2, folllistatin, granulocyte colony stimulat-
ing factor (G-CSF), hepatocyte growth factor (HGF), (inter-
leukin) IL-8, leptin, platelet-derived growth factor (BB 
dimeric subtype) (PDGF-BB), platelet endothelial cell adhe-
sion molecule (PECAM), VEGF-A in the laboratory of Dr. 
Debabrata Mukhopadhyay (Mayo Clinic, Rochester, MN). 
The assay was carried out according to the manufacturer’s 
instructions and all samples, including standards, were 
plated in triplicate. Data were acquired using the Luminex 
software system.
Statistical Methods
A 2:1 randomization scheme (A: B) was used to assess 
the primary end point of confirmed objective overall response 
rate (ORR) using RECIST 1.0.16 A maximum of 28 patients 
randomized to arm B would provide an estimate of the ORR 
within 19% points with 90% confidence. Using a one-stage 
Fleming design, a sample size of 56 patients in arm A pro-
vided 86% power to detect a true ORR of at least 40% (if 
the observed ORR in arm B was 25%), with a type I error 
rate of 0.09. Arm A would be declared promising if at least 
19 successes were observed. For the secondary end point of 
6-month progression-free survival (PFS6) rate, assuming an 
exponential model, a sample of 56 evaluable patients in arm 
A also provided 86% power to test that the true PFS6 rate is 
at most 25% versus the alternative hypothesis that the PFS6 
rate is at least 40% with a type I error rate of 0.09. Secondary 
end points included adverse event (AE) profile, overall sur-
vival (OS), progression-free survival (PFS), and duration of 
response.
Confirmed response, per RECIST 1.0, was defined 
as a complete or partial response noted on two consecutive 
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evaluations at least 4 weeks apart. PFS6 rate considered patients 
who terminated treatment before 6 months postrandomization 
for reasons other than disease progression as failures regardless 
of their progression status at 6 months. OS time was defined 
as the time from registration to death by any cause. PFS was 
defined as the time from registration to the first date of disease 
progression or death as a result of any cause. PFS was censored 
at the date of the last contact for patients alive and progression-
free at the time of this analysis. The distributions of PFS and 
OS were estimated using the Kaplan–Meier (KM) method, and 
compared between the arms in an exploratory fashion using the 
stratified log-rank test (adjusting for the stratification factors 
of ECOG PS [0 versus 1] and history of adjuvant/neoadjuvant 
therapy [yes versus no]). The AEs (regardless of attribution) 
were summarized as maximum severity per subject and type, 
across the duration of intervention for each arm and compared 
using Fisher’s exact test.
Aggregate fluorescence values for the angiogenesis 
markers (analytes) (measured on a continuous scale) were ana-
lyzed. Exploratory Cox proportional hazards model, adjusted 
for plate number and well location, was used to assess the 
impact of the levels of the analytes at baseline, before cycle 
3 (using a landmark approach), and percentage increase from 
baseline to cycle 3 (using a landmark approach) on OS and 
PFS. Logistic regression models were used to compare the 
adverse event (AE) patterns between the SNP subgroups. KM 
curves and Cox proportional hazards models were used to 
compare the OS and PFS distributions between the different 
tagSNP subgroups.
p Values less than or equal to 0.05 were considered 
statistically significant for the primary efficacy and AE com-
parisons, and p values less than or equal to 0.02 were consid-
ered promising for the correlative analyses. No adjustments 
for multiple comparisons were performed for the exploratory 
correlative analyses.
RESULTS
N0528 was activated on June 15, 2007 and completed 
accrual on December 5, 2008. Data for this report were fro-
zen on September 13, 2011. The Consolidated Standards of 
Reporting Trials (CONSORT) trial flow diagram is shown in 
Figure 1.
FIGURE 1.  CONSORT trial flow 
diagram.
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Lead-In Phase
Ten patients were accrued (7 in arm A, 3 in arm B). 
Cediranib 45 mg was administered once daily in arm A. One 
patient in arm A withdrew consent before starting therapy and 
was excluded. One patient treated on arm A had a protocol-
defined DLT (grade 3 diarrhea and nausea causing a dose inter-
ruption of > 14 days in cycle 1), and only one of the six patients 
on arm A completed two cycles at full doses of cediranib. Thus, 
the starting cediranib dose of 45 mg was not tolerable and was 
reduced to 30 mg once daily on a continuous schedule for the 
phase II portion of the study. These patients were not included 
in the analysis for the phase II portion of the study.
Phase II Portion
Patient and treatment characteristics
Ninety-one patients were randomized (60 arm A, 31 
arm B). Two patients from each arm were removed from the 
analysis because of either withdrawal of consent or never 
receiving study treatment (Fig. 1). Data from 58 patients in 
arm A and 29 patients in arm B are included here. Patient 
characteristics, treatment, and follow-up data are summarized 
in Table 1. There were no significant differences in baseline 
patient characteristics between the arms, except for distribu-
tion of histologic subtype.
Clinical outcomes–primary and secondary end 
points
The confirmed ORR in arms A and B among all the 
evaluable patients was 19% (n = 11; 95% confidence interval 
[CI]: 10%–31%) and 20% (n = 6; 95% CI: 8%–40%) (p = 1.0). 
The PFS6 rate among the first 56 evaluable patients in arm A 
was 46% (26; 95% CI: 33%–60%), thus meeting the protocol-
specified secondary end point. The PFS6 rate among all evalu-
able patients in arms A and B was 48% (95% CI: 35%–62%) 
and 38% (95% CI: 21%–58%) (p = 0.49), respectively.
Median PFS was 6.3 months (A, 95% CI: 4.7–7.9) 
versus 4.5 months (B, 95% CI: 2.6–7.2), (stratified log rank 
p = 0.11) (Fig. 2A). Median OS was 12 months (A, 95% CI: 
7.5–20.6) versus 9.9 months (B, 95% CI: 5.4–13.7), (stratified 
log rank p = 0.10) (Fig. 2B).
Adverse events
A total of 54 (A, 93%) and 26 (B, 90%) patients had 
grade 3 or higher AEs (Table 2). Grade 3+ nonhematologic 
AEs were higher in arm A (71% versus 45%, p = 0.01). The 
most common grade 3 and 4 nonhematologic AEs in arm A 
were fatigue (13.8%) and dyspnea (10.3%). The most com-
mon grade 3 and 4 AEs in arm B was fatigue (10.3%). Grade 2 
AEs (at least possibly related to treatment) as maximum occur-
rence were reported in four patients in arm A and two patients 
in arm B. In arm A, these were fatigue (5.4%), hypothyroidism 
(1.7%), oral mucositis (1.7%), neutropenia (3.4%), anorexia 
(1.7%), and dyspnea (1.7%). Grade 2 anemia was reported in 
both groups (3.4% in arm A, 6.9% in arm B).
Treatment was discontinued because of AE in a greater 
proportion of arm A patients (55% versus 10%, p = 0.0001). 
Of the 49 patients in arm A who started cycle 2, 18 (37%) con-
tinued cediranib 30 mg once daily, 22 (45%) decreased dosage 
to 20 mg, seven were dosed at 15mg, and two did not receive 
any further cediranib. Of the 38 patients who started cycle 
3, five(13%) were receiving cediranib 30 mg once daily, 25 
(66%) were dosed at 20 mg, seven were at 15mg, and one did 
not receive any cediranib. The most common reasons for dose 
adjustments were nonhematologic AEs (14%) and thrombocy-
topenia (12%) in cycle 1. Neutropenia and/or thrombocytope-
nia were the most common reasons for dose adjustments in the 
subsequent cycles. There was no significant interaction of AE 
with histology although this analysis is limited by the small 
number (n = 17) of patients with squamous cell histology.
TABLE 1.  Baseline Patient Characteristics and Treatment and 
Follow-Up
A (n=58) B (n=29) p
Patient characteristics
Age 0.48a
Median 65.0 64.0
Range (46.0–81.0) (45.0–82.0)
Sex 0.75b
Female 26 (44.8%) 12 (41.4%)
Male 32 (55.2%) 17 (58.6%)
Performance score 0.87b
0 33 (56.9%) 17 (58.6%)
1 25 (43.1%) 12 (41.4%)
Race 0.43c
White 55 (94.8%) 26 (89.7%)
Black or African American 3 (5.2%) 2 (6.9%)
Unknown: patient unsure 0 (0.0%) 1 (3.4%)
Before adjuvant treatment 1.00c
Yes 2 (3.4%) 1 (3.4%)
No 56 (96.6%) 28 (96.6%)
Cell type 0.02c
Squamous 9 (15.5%) 8 (27.6%)
Adenocarcinoma 22 (37.9%) 16 (55.2%)
All other 27 (46.6%) 5 (17.2%)
Treatment/follow-up
Follow-up time (in mo) for 
alive patients
0.42a
Median 33.4 31.9
Range (3.9–38.1) (30.8–33.1)
Reason for end of treatment 0.0002c
Completed study per protocol 5 (8.6%) 10 (34.5%)
Refused further treatment 5 (8.6%) 2 (6.9%)
Adverse event 32 (55.2%) 3 (10.3%)
Disease progression 13 (22.4%) 11 (37.9%)
Died on studyd 1 (1.7%) 2 (6.9%)
Other 2 (3.4%) 1 (3.4%)
Treatment cycles received 0.91a
Median 3.5 4.0
Range (1.0–20.0) (1.0–6.0)
aWilcoxon rank sum test.
bχ2 test.
cFisher’s exact test.
dReasons: disease progression (arm A). Death not otherwise specified and death 
from pulmonary hemorrhage, both deemed not related to study treatment (arm B).
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Correlative outcomes
Thirty-six patients (26 arm A, 10 arm B) had complete 
angiogenesis marker analyses and 52 patients (38 in arm A, 14 
in arm B) had sufficient DNA for SNP analysis. A comparison 
between patients with and without adequate specimens for the 
correlative studies revealed no significant differences in the 
underlying clinical and demographic variables.
Angiogenesis markers. Because of small sample size, 
data were combined across arms for this analysis. Baseline 
levels of the angiogenesis markers had no prognostic value. 
Patients with higher levels of follistatin before start of cycle 3 
had improved subsequent OS and PFS (hazard ratio [HR]=0.81 
for a 20-unit increase; p ≤ 0.02). Patients with higher levels 
of IL-8 and PDGF-BB before start of cycle 3 had worse OS 
(HR=1.37 for a 10-unit increase in IL-8; adjusted HR=1.21 
for a 50-unit increase in PDGF-BB; p ≤ 0.02). Patients with a 
higher percentage increase in VEGF-A before start of cycle 3 
compared with baseline had better subsequent PFS (HR=0.88 
for 20-unit increase; p = 0.02).
Genetic polymorphisms: TagSNPs and distribution of 
variants. One hundred and twenty tagSNPs generated from 
the nine genes with minor allele frequency greater than 5% 
were successfully genotyped. The distribution of genotypes is 
shown in the Supplemental Table 1 (Supplementary Digital 
Content 1, http://links.lww.com/JTO/A349). Except for one 
SNP,  rs7012413 in FGFR1, all other SNPs genotyped were in 
Hardy-Weinberg equilibrium. Genotypes observed in less than 
five patients were regrouped and if the regrouped frequency 
was less than or equal to 10%, the SNP was excluded from 
the analyses with the clinical outcomes. When the genotypes 
were relevant to arm A alone (FLT1, KDR, FLT4 (VEGFR1-
3), VEGFA, FGFR1-3), data were analyzed within arm A, and 
combined across arms otherwise (ABCB1, ABCC1).
At p value less than or equal to 0.02, four polymor-
phisms, rs2235015 in ABCB1, rs17542768 and rs2071616 in 
FGFR2, and rs3024987 in VEGFA were significantly asso-
ciated with reduced toxicities (Table 3), whereas four other 
polymorphisms in FGFR1 (rs7012413), FGFR2 (rs2912791, 
rs2981429), and FLT4/VEGFR3 (rs11748431) were 
FIGURE 2.  Kaplan–Meier curves 
in overall population for (A) pro-
gression-free survival and (B),overall 
survival.
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significantly associated with survival outcomes (Table 4). 
Variant alleles in FGFR1 rs7012413, FGFR2 rs2912791, and 
FLT4 (VEGFR3) rs11748431 SNPs correlated with inferior 
OS, however, the variant allele in FGFR2 rs2981429 SNP was 
associated with superior PFS (Table 4), Fig. 3 shows the KM 
plots for OS according to pertinent SNP.
DISCUSSION
The results of E4599 have spurred clinical development 
of angiogenesis inhibitors in lung cancer therapy. However, 
significant progress has yet to be made, particularly for small-
molecule VEGFR inhibitors. The phase III Evaluation of 
Sorafenib, Carboplatin and Paclitaxel Efficacy in NSCLC 
(ESCAPE) study of first-line carboplatin and paclitaxel with 
or without the multikinase inhibitor sorafenib17 was terminated 
early because of lack of benefit at interim analysis. Subgroup 
analyses showed an association between squamous histology 
and excess mortality and inferior survival with sorafenib. 
The phase III MOtesanib NSCLC Efficacy and Tolerability 
Study (MONET1) study of carboplatin and paclitaxel with or 
without motesanib, another multikinase inhibitor, suffered a 
similar fate.18 Interim analysis in 2008 led to its temporary 
suspension because of more deaths in squamous histology 
patients on the treatment arm. The study was reopened in 
February 2009 to patients with nonsquamous histology only, 
but final analysis of the 1090 nonsquamous patients showed 
no benefit to the addition of motesanib.19
BR.24 was a phase II/III double-blind study 
investigating the addition of 45 mg daily cediranib to first-line 
carboplatin and paclitaxel.20 The study was amended early to 
cediranib 30 mg daily and to exclude poor PS patients because 
of toxicities of hypertension, thrombocytopenia, hemoptysis, 
dermatologic, and gastrointestinal AEs. Despite the increase 
in serious AEs, including fatalities in the cediranib arm, 
the phase II interim analysis revealed a significantly higher 
response rate with an HR of 0.77 for PFS in the cediranib 
arm (95% CI: 0.56–1.08), regardless of histology. However, 
because of the poor tolerance of even the 30 mg dose, the phase 
III placebo-controlled BR.29 study used cediranib at 20 mg in 
combination with carboplatin and paclitaxel. Our experience 
similarly reflected increased toxicity of cediranib at the 
30 mg once daily dosing in combination with carboplatin and 
gemcitabine, with nearly half of initial cohort requiring dose 
reduction to 20 mg once daily by the second cycle of treatment 
and nearly fivefold increased rate of treatment discontinuation 
TABLE 2.  Adverse Events by Arm
A (n = 58) B (n = 29) p
Overall in all patients
Grade 3+ 54 (93.1%) 26 (89.7%) 0.68a
Grade 4+ 38 (65.5%) 16 (55.2%) 0.34b
Grade 3+ hematologic 44 (75.9%) 20 (69.0%) 0.49b
Grade 4+ hematologic 32 (55.2%) 12 (41.4%) 0.22b
Grade 3+ nonhematologic 41 (70.7%) 13 (44.8%) 0.01b
Grade 4+ nonhematologic 11 (19.0%)  5 (17.2%) 0.84b
Occurring in at least 10% of 
patients
Fatigue grade 3+  8 (13.8%)  3 (10.3%) 0.74a
Anemia grade 3+  6 (10.3%)  8 (27.6%) 0.03b
Leukopenia grade 3+ 28 (48.3%) 12 (41.4%) 0.54b
Neutropenia grade 3+ 35 (60.3%) 13 (44.8%) 0.17b
Thrombocytopenia grade 3+ 33 (56.9%) 13 (44.8%) 0.28b
*Fisher’s exact test.
bχ2 test.
TABLE 3.  Genotype and Adverse Event End Pointsa
Adverse Event (Treatment Arm) Genotype (n)
Number of Events  
(% Between Allele Groups)
Odds Ratio  
(95% CI) pb
Grade 3+ adverse arm A FGFR2: rs17542768
GA+GG (10)  7 (20.6) 0.086 (0.008–0.963) 0.0194
AA (28) 27 (79.4) Reference (—)
Grade 3+ hematologicarm A FGFR2: rs2071616
GA+AA (21) 12 (42.9) 0.083 (0.009–0.750) 0.0101
GG (17) 16 (57.1) Reference (—)
VEGFA: rs3024987
TC+TT (12)  5 (17.9) 0.093 (0.018–0.491) 0.0023
CC (26) 23 (82.1) Reference (—)
Grade 3+ nonhematologicarm A FGFR2: rs17542768
GA+GG (10)  4 (14.8) 0.145 (0.029–0.712) 0.0117
AA (28) 23 (85.2) Reference (—)
Grade 3+ nonhematologic arm A+B ABCB1: rs2235015
GT+TT (16)  6 (18.8) 0.185 (0.051–0.668) 0.0074
GG (34) 26 (81.3) Reference (—)
ap < 0.02 shown.
bFisher’s exact p value.
CI, confidence interval.
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because of toxicity in this arm compared with the control 
group.
Although the current study is not powered for survival 
estimates, results presented here affirm the majority of the 
findings in BR.24, with PFS and OS trends favoring the cedi-
ranib arm (PFS: HR=0.69, 95% CI: 0.43–1.09; OS: HR=0.66, 
95% CI: 0.41–1.08) but with more toxicity in the cediranib 
arm. Of note, the aforementioned BR.29 trial was recently 
halted because of the futility in achieving its OS end point 
based on interim analysis of the PFS data despite achieving 
an increased ORR with the combination of cediranib at the 
reduced 20-mg daily dose.21 The need to further reduce the 
dose of cediranib to 20 mg in most patients attests to the fre-
quent observation that doses established with short-term use 
during early clinical development may not prove feasible in 
clinical practice with chronic dosing. Moreover, such toxici-
ties can undermine overall clinical benefit despite improve-
ment in surrogate end points, as seen in BR.29.
Our analysis of angiogenesis biomarkers supported 
observations from other studies. Follistatin is a single-chain 
glycoprotein that can enhance endothelial cell prolifera-
tion.22,23 Whereas baseline follistatin levels had no prognostic 
value, patients with higher post-treatment levels had better 
survival, which may be explained by mouse models demon-
strating increased apoptosis, and suppression of angiogen-
esis, and metastasis in follistatin-dependent tumors.22,24 In 
contrast, elevated levels of plasma IL-8, a proinflammatory 
chemokine,25,26 had been correlated with poor outcomes in a 
variety of clinical settings,27–29 a finding confirmed in our study. 
PDGF-BB is a mitogenic factor that synergizes with FGF2 to 
promote tumor neovascularization.30–32 Worse outcome among 
patients with higher post-treatment PDGF-BB may be attrib-
utable to the activation of angiogenic switch, such as through 
FGF signaling, which had been postulated to accelerate the 
development of a more aggressive phenotype.33,34 However, 
serum or plasma VEGF levels are not consistently predictive 
of outcome and their predictive and prognostic value may be 
dependent on tumor type.35–42
Existing literature has reported prognostic and predic-
tive associations of VEGFA and VEGFR polymorphic variants 
to therapy with anti-VEGF agents.43–45 and these results further 
contribute to those observations. We observed that an intron 1 
polymorphism in VEGFA was associated with reduced hema-
tologic toxicity and an intron 1 polymorphism inVEGFR3 was 
associated with decreased survival. Furthermore, an intron 5 
polymorphism in ABCB1 was also associated with reduced 
risk of nonhematologic toxicities in both treatment groups. A 
variety of ABCB1 polymorphisms had been correlated with 
treatment response and toxicities using platinum-based regi-
mens in lung cancer patients.46–48 Finally, reports indicate that 
FGFR1 amplification is a common genetic event and associ-
ated with tumor growth and survival in squamous cell lung 
cancer.49–51 On the basis of our exploratory analysis, we further 
report that certain genetic variants of FGFR1 and FGFR2 may 
also be correlated not only with treatment toxicity, but also 
with prognostic outcomes to cediranib therapy in NSCLC. 
TABLE 4.  Genotype and Time to Event End Pointsa
Time Event  
(Treatment Arm) Genotype (N)
Number of Events (% 
between Allele Groups) Median (95% CI)b
Hazard Ratio  
(95% CI)c pd
Overall survival arm A FGFR1: rs7012413
CT+TT (27) 23 (85.2) 7.5 (5.3–14.0) 3.94 (1.35–11.51) 0.0071
CC (11)  4 (14.8) 25.3 (7.1–N/A) Reference (—)
FGFR2: rs2912791
CT (20) 14 (51.9) 14.2 (6.9–25.3) 0.66 (0.26–1.72) 0.0002
TT (6)  6 (22.2) 4.5 (1.3–8.1) 5.01 (1.54–16.28) (—)
CC (11)  7 (25.9) 17.8 (5.1–N/A) Reference (—)
FLT4(VEGFR3): rs11748431
AG+AA (15) 14 (51.9) 7.1 (5.1–9.2) 2.78 (1.24–6.23) 0.0095
GG (23) 13 (48.1) 14.3 (6.5–N/A) Reference (—)
Progression-free survival  
arm A
FGFR2: rs2912791
CT (20) 17 (53.1) 8.5 (4.7–14.1) 0.55 (0.24–1.27) 0.0010
TT (6)  6 (18.8) 2.2 (1.3–5.5) 3.64 (1.17–11.26) (—)
CC (10)  9 (28.1) 5.8 (0.7–7.1) Reference (—)
FGFR2: rs2981429
CT (20) 17 (51.5) 8.4 (4.7–14.1) 0.27 (0.11–0.66) 0.0106
TT (8)  7 (21.2) 6.1 (0.7–17.9) 0.41 (0.15–1.16) (—)
CC (9)  9 (27.3) 4.7 (1.3–6.3) Reference (—)
aOnly p < 0.02 shown.
bKaplan–Meier method.
cCox model.
dScore p value.
CI, confidence interval.
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Thus an FGFR1 intron 1 polymorphism was associated with 
decreased survival, whereas polymorphisms in introns 2, 4, 
and 6 of FGFR2 were associated with better survival and 
reduced toxicities.
In summary, cediranib in combination with gem-
citabine and carboplatin at the 30-mg daily dose tested in 
this study was significantly more toxic than chemotherapy 
alone. Furthermore, this combination did not demonstrate 
FIGURE 3.  Kaplan–Meier curves 
for overall survival according to 
polymorphic variants A, FGFR1 
rs7012413, (B) FGFR2 rs2912791, 
and (C) VEGFR3 rs11748431.
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improvement in ORR compared with chemotherapy alone 
in an unselected NSCLC population. The prognostic sig-
nificance of FGFR1 and VEGFR polymorphisms should be 
further investigated in future studies involving VEGFR and 
FGFR kinase inhibitors.
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